You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. STING Activators as Therapy for Cancer

    SBC: STINGINN, LLC            Topic: 102

    PROJECT SUMMARY The Immuno-oncology (IO) arena affords a new and exciting approach to stimulate the body’s own immune system to fight cancer. The generation of anti-cancer T cells is predominantly triggered by phagocytosed cancer cells stimulating innate immune signaling pathways in professional antigen presenting cells (APC’s). This signaling process is largely governed by STING (stimulator o ...

    STTR Phase II 2022 Department of Health and Human ServicesNational Institutes of Health
  2. Adipokine-enriched brown adipocytes for treating polycystic ovary syndromes

    SBC: BioRestorative Therapies, Inc.            Topic: NICHD

    Abstract Polycystic ovary syndromes (PCOS) affect 6-18% of reproductive age female, representing the most common endocrine disease in this population. PCOS causes gynecological, dermatologic and metabolic comorbidities, and also imposes long-term risks of diabetes mellitus type 2 (T2D), cardiovascular diseases (CVD) and psychiatric problems including severe depression. PCOS is related to complex h ...

    SBIR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
  3. Development of a first-in-class nonmuscle myosin II inhibitor to prevent substance use disorder relapse

    SBC: MYOSIN THERAPEUTICS INC.            Topic: NIDA

    PROJECT SUMMARY In 2018, over 1 million people in the U.S. qualified as having a methamphetamine (METH) use disorder and rates of METH use are surging, largely in response to the opioid epidemic. METH use disorder is a chronic condition for which there are currently no FDA-approved medications. The only treatment options available are behavioral modification therapies, which have limited efficacy, ...

    SBIR Phase II 2022 Department of Health and Human ServicesNational Institutes of Health
  4. An AI-based Multimodal Approach to Predict Pain in Postnatal Care Scenarios

    SBC: Stereology Resource Center, Inc            Topic: NICHD

    PROJECT SUMMARY Advances in technology and surgical procedures in the past decade have led to a remarkable increase in numbers of newborns subjected to lifesaving surgery. These postoperative neonates are customarily triaged to neonatal intensive care units (NICUs) for pain management with opioids, primarily morphine, fentanyl, and methadone. However, substantial evidence from in- vitro, animal, a ...

    STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
  5. The Development and Systematic Evaluation of an AI-Assisted Just-in-Time-Adaptive-Intervention for Improving Child Mental Health

    SBC: Colliga Apps Corp.            Topic: NIMH

    PROJECT SUMMARY/ABSTRACT Early childhood mental health problems constitute a significant public health concern with wide-ranging impacts on functioning both concurrently and later in life. Although childhood mental health is influenced by a variety of factors, the quality of relationships with caregivers plays a critical role. Critical, coercive, and conflictual parent- child interactions have bee ...

    SBIR Phase II 2022 Department of Health and Human ServicesNational Institutes of Health
  6. Improving Outcomes in Cancer Treatment-Related Cardiotoxicity

    SBC: LightSeed, Inc.            Topic: NHLBI

    Project Summary/Abstract Anthracyclines, such as Doxorubicin (DOX), are effective for the treatment of many cancers (Ovarian, Multiple Myeloma, Kaposi Sarcoma, Leukemia, Bone Sarcoma, Breast, Endometrial, Gastric, Liver, Kidney, and other Cancers). The global DOX market is increasing annually and expected to reach $1.3B by 2026. DOX toxicity is therefore relevant to a broad number of cancers. Howe ...

    SBIR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
  7. EaseAlert: Tactile Firefighter Alerting System Designed to Reduce Negative Cardiovascular Outcomes and Sleep Disturbances

    SBC: EASEALERT LLC            Topic: NHLBI

    Project Abstract Sudden cardiac death (SCD) has been the leading cause of on-duty death (ODD) in the fire service over the past several decades, accounting for 51.6% of all ODDs in 2019. The primary factors that contribute to SCD among firefighters are overexertion and stress, and SCD is most likely to occur during fire suppression and alarm response. When an emergency occurs, firefighters are ale ...

    SBIR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
  8. Development of a lead candidate for the treatment of Alzheimer's disease

    SBC: Vova Ida, LLC            Topic: NIA

    SUMMARY Alzheimer’s disease (AD) is an age-related neurodegenerative disease that has become a global epidemic with over 40 million people affected worldwide and a projected 115 million in 2050. It is the 6th leading cause of death in the United States. AD has a tremendous impact on health, society and the economy. Approved treatments at best partially ameliorate some symptoms. There is an urgen ...

    STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
  9. Entrepreneurial development award for a novel Alzheimer's disease therapeutic

    SBC: BOLDEN THERAPEUTICS, INC.            Topic: Y

    The aging population in the US and globally has led to an urgent need for therapeutics to prevent and treat Alzheimer's disease (AD). Adult Hippocampal Neurogenesis (AHN) is critical for normal learning and memory and declines in patients with AD. Work in animal models has underscored the role of AHN in improving cognition in the face of AD pathology. Thus, restoring AHN has emerged as an attracti ...

    SBIR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
  10. Deep-CDS: Deep Learning Semantic Data Lake for Clinical Decision Support

    SBC: INFOTECH SOFT, INC.            Topic: 300

    More than 5 million patients are admitted annually to United States ICUs with average mortality rate reported ranging from 8-19%, or about 500,000 deaths annually. Sepsis is the leading cause of in-hospital mortality, where one in three inpatient deaths are due to sepsis. Incidence of sepsis has been increasing with 1.7 million sepsis cases and 270,000 deaths per year. Early identification of dete ...

    SBIR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government